Top

Published in:

01-09-2010 | Correspondence

The Authors’ Reply

Authors: Laura McCullagh, Lesley Tilson, Cathal Walsh, Michael Barry

Published in: PharmacoEconomics | Issue 9/2010

Excerpt

We are grateful to the editors for the opportunity to comment on the correspondence from Plumb et al.[1] The authors indicate that health technology assessment (HTA) agencies such as the UK National Institute for Health and Clinical Excellence (NICE) and the Scottish Medicines Consortium (SMC) approved the use of dabigatran for the prophylaxis of venous thromboembolism (VTE) after total hip replacement (THR) and total knee replacement (TKR). They will be pleased to note that the National Centre for Pharmacoeconomics in Ireland also issued a positive recommendation that resulted in reimbursement of dabigatran for this indication.[2] …

Plumb JM, Clemens A, Monz BU. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review [letter]. Pharmacoeconomics 2010; 28 (9): 781–2PubMedCrossRef

The National Centre for Pharmacoeconomics (NCPE) in Ireland. Economic evaluation on the cost effectiveness of dabigatran etexilate (Pradaxa®) for the primary prevention of venous thromboembolic events in adult patients who have undergone total hip replacement or total knee surgery. Dublin: NCPE, 2008 Sep [online]. Available from URL: http://www.ncpe.ie/u_docs/doc_159.pdf [Accessed 2010 Jul 23]

McCullagh L, Tilson L, Walsh C, et al. A cost-effectiveness analysis model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009; 27 (10): 829–46PubMedCrossRef

McCullagh L, Tilson L, Walsh C, et al. Cost effectiveness of rivaroxaban and dabigatran etexilate for the prophylaxis of venous thromboembolism and associated long term complications post total hip replacement in Ireland [poster presentation]. ISPOR 12th Annual European Congress; 2009 Oct 24-27; Paris

McCullagh L, Walsh C, Barry M. An application of value of information analysis to decrease uncertainty [poster presentation]. HTAi 7th Annual Meeting; 2010 Jun 6-9; Dublin

Adams R, Walsh C, Veale D, et al. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis. Pharmacoeconomics 2010; 28 (6): 477–87PubMedCrossRef

Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683–91PubMedCrossRef

Prandoni P, Villata S, Bagatella P, et al. The clinical course of deep vein thrombosis, prospective long term follow up of 528 symptomatic patients. Haematologica 1997; 82: 423–8PubMed

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–51PubMedCrossRef

Title: The Authors’ Reply
Authors: Laura McCullagh
Lesley Tilson
Cathal Walsh
Michael Barry
Publication date: 01-09-2010
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 9/2010
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.2165/11535720-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Authors’ Reply

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2010

Using Conjoint Analysis and Choice Experiments to Estimate QALY Values

A New Method for Examining the Cost Savings of Reducing COPD Exacerbations

Cost Effectiveness of Adjunctive Quetiapine Fumarate Extended-Release Tablets with Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder

An Economic Evaluation of Colesevelam when Added to Metformin-, Insulinor Sulfonylurea-Based Therapies in Patients with Uncontrolled Type 2 Diabetes Mellitus

Frequency of Treatment-EffectModification Affecting Indirect Comparisons

Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement: A Systematic Review